Arcutis Biotherapeutics Inc (NASDAQ:ARQT) price closed higher on Friday, May 16, and jumping 3.52% above its previous close.
A look at the daily price movement shows that the last close reads $13.63. Taking into account the 52-week price action we note that the stock hit a 52-week high of $17.75 and 52-week low of $6.99. The stock added 8.87% on its value in the past month.
Arcutis Biotherapeutics Inc, which has a market valuation of $1.68 billion, is expected to release its quarterly earnings report in June.
Technical indicators in stocks provide crucial insights into market trends, guiding investors with precise entry and exit points based on price movements for informed decision-making.On the technical perspective front, indicators give ARQT a short term outlook of Hold on average. Looking at the stock’s medium term indicators we note that it is averaging as a 50% Buy, while an average of long term indicators are currently assigning the stock as 50% Buy.
Here is a look at the average analyst rating for the stock as represented on a scale of 1.00 to 5.00, with the extremes of 1.00 and 5.00 suggesting the stock is strong buy or strong sell respectively. Specifically, 3 analysts have assigned ARQT a recommendation rating as follows: 0 rate it as a Hold; 2 advise Buy while 0 analyst(s) assign an Overweight rating. 0 analyst(s) have tagged the Arcutis Biotherapeutics Inc (ARQT) stock as Underweight, with 1 recommending Sell. In general, analysts have rated the stock Buy, a scenario likely to bolster investors out for an opportunity to add to their holdings of the company’s shares.
The overview shows that ARQT’s price is at present -1.07% off the SMA20 and -4.43% from the SMA50. The Relative Strength Index (RSI) metric on the 14-day timeframe is pointing at 49.14, with weekly volatility standing at 5.48%. The indicator jumps to 6.24% when calculated based on the past 30 days. Arcutis Biotherapeutics Inc (NASDAQ:ARQT)’s beta value is holding at 1.78, while the average true range (ATR) indicator is currently reading 0.95. Considering analysts have assigned the stock a price target range of $19-$19 as the low and high respectively, we find the trailing 12-month average consensus price target to be $19. Based on this estimate, we see that current price is roughly -34.66% off the estimated low and -34.66% off the forecast high. Investors will no doubt be excited to see the share price fall to $19, which is the median consensus price, and at that level ARQT would be -34.66% from current price.
An analysis of the Arcutis Biotherapeutics Inc (NASDAQ:ARQT) stock in terms of its daily trading volume indicates that the 3-month average is 2.42 million.
Current records show that the company has 119.14M in outstanding shares. The insiders’ percentage holdings are 12.05% of outstanding shares while the percentage share held by institutions stands at 99.13%. But the 1.29% upside, the stock’s price has registered year-to-date as of last trading, will likely reignite investor interest given the prospect of it rallying even higher.
